Last reviewed · How we verify
Kinisoquin™
Kinisoquin is a small molecule inhibitor of the sodium-glucose cotransporter 2 (SGLT2).
Kinisoquin is a small molecule inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Treatment of type 2 diabetes.
At a glance
| Generic name | Kinisoquin™ |
|---|---|
| Also known as | Isoquercetin |
| Sponsor | Quercis Pharma AG |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, Kinisoquin reduces glucose reabsorption in the kidneys, leading to increased glucose excretion in the urine and decreased blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.
Approved indications
- Treatment of type 2 diabetes
Common side effects
- Increased risk of diabetic ketoacidosis
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Kinisoquin™ CI brief — competitive landscape report
- Kinisoquin™ updates RSS · CI watch RSS
- Quercis Pharma AG portfolio CI